WilmerHale Advises Patient Square Capital's Platform Enavate Sciences on $125 Million Series A Financing for Ambros Therapeutics

WilmerHale Advises Patient Square Capital's Platform Enavate Sciences on $125 Million Series A Financing for Ambros Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Patient Square Capital's platform Enavate Sciences in its co-led, oversubscribed $125 million Series A financing to launch Ambros Therapeutics (Ambros). Ambros is a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases, beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The financing is expected to support the neridronate pivotal Phase 3 clinical trial in CRPS-1 (CRPS-RISE), as well as related regulatory preparations and pre-commercial activities.

The WilmerHale team was led by Palo Alto Partners Daniel Zimmermann and Jekkie Kim and included Associate Ben Goldfein.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel